23:17 , Apr 8, 2019 |  BC Extra  |  Company News

Zogenix gets refusal-to-file letter for Dravet syndrome therapy

Zogenix was off $16.11 (31%) to $35.74 in early after-hours trading Monday after the company said FDA issued a refusal-to-file letter for an NDA for Fintepla (ZX008) to treat seizures associated with Dravet syndrome. Fintepla...
19:02 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Aug. 7th. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill...
03:27 , Aug 8, 2018 |  BC Extra  |  Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Tuesday. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill Lynch,...
19:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Zogenix to advance regulatory plans on second Phase III win

Zogenix Inc. (NASDAQ:ZGNX) reported top-line data showing ZX008 as an adjunctive therapy to stiripentol regimen met the primary endpoint in its second Phase III trial, Study 1504, to treat Dravet syndrome. Daily 0.5 mg/kg oral...
20:34 , Jul 12, 2018 |  BC Extra  |  Clinical News

Zogenix market cap grows with second Phase III win

Zogenix Inc. (NASDAQ:ZGNX) gained $9.60 (21%) to $55.90 on Thursday, adding about $338 million in market cap, after it reported top-line data showing ZX008 as an adjunctive therapy to stiripentol regimen met the primary endpoint...
19:28 , Jul 3, 2018 |  BC Extra  |  Company News

Management tracks: Cigna, Novocure, Voyager

Health services company Cigna Corp. (NYSE:CI) appointed Mark McClellan to its board, effective the earlier of Dec. 1 or the close of Cigna's acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). McClellan is director of the...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
16:18 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

FDA grants breakthrough therapy designation to Zogenix's ZX008

Zogenix Inc. (NASDAQ:ZGNX) said FDA granted breakthrough therapy designation to ZX008 to treat seizures associated with Dravet syndrome. The designation is based on data from the Phase III Study 1 to treat Dravet syndrome showing...
16:26 , Jan 12, 2018 |  BC Week In Review  |  Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
23:54 , Jan 9, 2018 |  BC Extra  |  Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...